BioMarin PharmaceuticalsBMRN
BMRN
About: BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments aimed at addressing complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria (PKU), hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development.
Employees: 3,040
0
Funds holding %
of 7,433 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
30% more repeat investments, than reductions
Existing positions increased: 236 | Existing positions reduced: 182
17% more funds holding in top 10
Funds holding in top 10: 6 [Q1] → 7 (+1) [Q2]
4% more first-time investments, than exits
New positions opened: 85 | Existing positions closed: 82
2% more call options, than puts
Call options by funds: $57.8M | Put options by funds: $56.6M
0.08% less ownership
Funds ownership: 96.07% [Q1] → 95.99% (-0.08%) [Q2]
2% less funds holding
Funds holding: 579 [Q1] → 569 (-10) [Q2]
21% less capital invested
Capital invested by funds: $12.9B [Q1] → $10.1B (-$2.74B) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$96
67%
upside
Avg. target
$107
87%
upside
High target
$114
98%
upside
4 analyst ratings
4 positive
100%
0 neutral
0%
0 negative
0%
Guggenheim Debjit Chattopadhyay | 85%upside $106 | Buy Maintained | 6 Aug 2025 |
UBS Eliana Merle | 98%upside $114 | Buy Maintained | 5 Aug 2025 |
Morgan Stanley Matthew Harrison | 67%upside $96 | Overweight Maintained | 22 Jul 2025 |
JP Morgan Jessica Fye | 97%upside $113 | Overweight Maintained | 14 Jul 2025 |
Financial journalist opinion
Based on 13 articles about BMRN published over the past 30 days
Positive
Zacks Investment Research
1 week ago
BioMarin Pharmaceutical (BMRN) is a Top-Ranked Momentum Stock: Should You Buy?
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Zacks Investment Research
1 week ago
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Positive
Zacks Investment Research
2 weeks ago
Why BioMarin Pharmaceutical (BMRN) is a Top Growth Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Positive
Seeking Alpha
3 weeks ago
BioMarin: Acquisition Of Inozyme Brings Forth Late-Stage ERT BMN 401
BioMarin's revenue growth is strong, with Q2 2025 revenues up 16% year-over-year and full-year guidance raised to $3.125–$3.2 billion. The Inozyme acquisition brings late-stage BMN 401 for ENPP1 deficiency, with pivotal phase 3 data expected in 1H 2026 and potential first-mover advantage. Voxzogo and Palynziq continue to drive growth, with label expansions and new pipeline candidates like BMN 333 poised to further bolster its pipeline.
Positive
Benzinga
3 weeks ago
BioMarin Discontinues Preclinical Drug Candidate, Advances BMN 333 Toward 2030
On Tuesday, Biomarin Pharmaceutical Inc. BMRN reported second-quarter adjusted earnings of $1.44, up 50% year over year, beating the consensus of 85 cents and sales of $825.41 million, up 16%, beating the consensus of $760.39 million.
Positive
Zacks Investment Research
3 weeks ago
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
Neutral
Seeking Alpha
3 weeks ago
BioMarin Pharmaceutical Inc. (BMRN) Q2 2025 Earnings Call Transcript
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN ) Q2 2025 Earnings Conference Call August 4, 2025 4:30 PM ET Company Participants Alexander Hardy - President, CEO & Director Brian R. Mueller - Executive VP of Finance & CFO Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Traci McCarty - Group Vice President Conference Call Participants Akash Tewari - Jefferies LLC, Research Division Alexandria Janet Hammond - Wolfe Research, LLC Allison Marie Bratzel - Piper Sandler & Co., Research Division Cory William Kasimov - Evercore ISI Institutional Equities, Research Division Ellen Horste - TD Cowen, Research Division Huidong Wang - Barclays Bank PLC, Research Division Jasmine Alexandra Fels - UBS Investment Bank, Research Division Jason Matthew Gerberry - BofA Securities, Research Division Konstantinos Biliouris - BMO Capital Markets Equity Research Olivia Simone Brayer - Cantor Fitzgerald & Co., Research Division Paul Andrew Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Sean M.
Positive
Zacks Investment Research
3 weeks ago
BioMarin (BMRN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Positive
Zacks Investment Research
3 weeks ago
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
BioMarin Pharmaceutical (BMRN) came out with quarterly earnings of $1.44 per share, beating the Zacks Consensus Estimate of $1.03 per share. This compares to earnings of $0.96 per share a year ago.
Positive
The Motley Fool
3 weeks ago
BioMarin (BMRN) Q2 Revenue Jumps 16%
BioMarin (BMRN) Q2 Revenue Jumps 16%
Charts implemented using Lightweight Charts™